AHA report demonstrates benefits of 340B program
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy arrangements.
“The 340B program plays an important public policy role in ensuring access to essential drugs and services for low-income and underserved Americans receiving care at 340B hospitals nationwide,” the report concludes. “Without the program, many patients could have trouble accessing affordable medications and critical health services, jeopardizing their health and well-being.”
Related News Articles
Perspective
With only 11 days that the House and Senate are in session together before the fiscal year concludes, much of the attention in Washington is on how Congress…
Headline
The Centers for Medicare & Medicaid Services has extended to Sept. 11 the deadline to submit comments on its proposed remedy for the unlawful payment…
Headline
AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would…
Headline
The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that…
Headline
A Modern Healthcare analysis of 340B hospitals “should be viewed with the derision it deserves,” writes AHA General Counsel and Secretary Melinda Hatton. “It…
Blog
Modern Healthcare’s putative report on CMS’ 340B remedy proposal is completely wrong and irresponsible for the following reasons.
First, to reach its…